NYSE:CLDI Calidi Biotherapeutics (CLDI) Stock Price, News & Analysis $1.57 +0.12 (+8.28%) Closing price 04:00 PM EasternExtended Trading$1.52 -0.05 (-3.18%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Calidi Biotherapeutics Stock (NYSE:CLDI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Calidi Biotherapeutics alerts:Sign Up Key Stats Today's Range$1.43▼$1.5750-Day Range$1.45▼$9.2652-Week Range$1.41▼$46.68Volume130,804 shsAverage Volume598,147 shsMarket Capitalization$5.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity. Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors. Both programs leverage the company’s proprietary immune activator to induce rapid cytokine release and recruitment of innate and adaptive immune cells at the tumor site. Preclinical studies have also demonstrated potential for a systemically delivered candidate under investigation for metastatic solid tumors. In addition, Calidi maintains a pipeline of preclinical programs exploring prophylactic and therapeutic applications against viral pathogens. Headquartered in South San Francisco, California, Calidi Biotherapeutics was founded to advance synthetic RNA-based immunomodulators into the clinic and is led by a management team with extensive experience in immuno-oncology drug development. The company collaborates with academic partners and contract manufacturing organizations to support clinical and regulatory activities. Calidi Biotherapeutics is publicly traded on the New York Stock Exchange under the symbol CLDI.AI Generated. May Contain Errors. Read More Calidi Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreCLDI MarketRank™: Calidi Biotherapeutics scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Calidi Biotherapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Calidi Biotherapeutics are expected to grow in the coming year, from ($4.48) to ($0.88) per share. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.69% of the float of Calidi Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverCalidi Biotherapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Calidi Biotherapeutics has recently increased by 39.81%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCalidi Biotherapeutics does not currently pay a dividend.Dividend GrowthCalidi Biotherapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.69% of the float of Calidi Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverCalidi Biotherapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Calidi Biotherapeutics has recently increased by 39.81%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 2 people have searched for CLDI on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows3 people have added Calidi Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Calidi Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $455,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.70% of the stock of Calidi Biotherapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.53% of the stock of Calidi Biotherapeutics is held by institutions.Read more about Calidi Biotherapeutics' insider trading history. Receive CLDI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calidi Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLDI Stock News HeadlinesCalidi Biotherapeutics (NYSE:CLDI) CEO Eric Poma Buys 25,000 SharesAugust 26, 2025 | insidertrades.comCalidi Biotherapeutics Updates Presentation DisclosureAugust 29, 2025 | tipranks.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.September 26 at 2:00 AM | Traders Agency (Ad)Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment OptionAugust 22, 2025 | markets.businessinsider.comCalidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment OptionAugust 21, 2025 | globenewswire.comCalidi prices 1.47M units at $2.00 in underwritten public offeringAugust 20, 2025 | msn.comCalidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public OfferingAugust 20, 2025 | globenewswire.comCalidi Biotherapeutics Secures FDA Fast Track DesignationAugust 17, 2025 | theglobeandmail.comSee More Headlines CLDI Stock Analysis - Frequently Asked Questions How have CLDI shares performed this year? Calidi Biotherapeutics' stock was trading at $13.80 at the beginning of the year. Since then, CLDI shares have decreased by 88.6% and is now trading at $1.57. How were Calidi Biotherapeutics' earnings last quarter? Calidi Biotherapeutics, Inc. (NYSE:CLDI) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($7.80) earnings per share for the quarter, beating the consensus estimate of ($10.20) by $2.40. When did Calidi Biotherapeutics' stock split? Calidi Biotherapeutics's stock reverse split on the morning of Monday, July 15th 2024.The 1-10 reverse split was announced on Monday, July 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Calidi Biotherapeutics' major shareholders? Calidi Biotherapeutics' top institutional investors include Armistice Capital LLC (26.17%), Bank of Montreal Can (1.16%), Geode Capital Management LLC (7.69%) and Quaker Wealth Management LLC. Insiders that own company stock include Scott Leftwich, Eric E Poma and Allan Camaisa. View institutional ownership trends. How do I buy shares of Calidi Biotherapeutics? Shares of CLDI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Calidi Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Calidi Biotherapeutics investors own include ARMOUR Residential REIT (ARR), AGNC Investment (AGNC), Avino Silver & Gold Mines (ASM), Carlyle Secured Lending (CGBD), Devon Energy (DVN), Hercules Capital (HTGC) and Main Street Capital (MAIN). Company Calendar Last Earnings11/12/2024Today9/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:CLDI Previous SymbolNYSE:CLDI CIK1855485 Webcalidibio.com Phone858-794-9600FaxN/AEmployees38Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.22 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-344.45% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.32) per share Price / Book-0.68Miscellaneous Outstanding Shares3,426,000Free Float20,039,000Market Cap$5.38 million OptionableN/A Beta1.08 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NYSE:CLDI) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.